Validation of Vitek 2 nonfermenting gram-negative cards and Vitek 2 version 4.02 software for identification and antimicrobial susceptibility testing of nonfermenting gram-negative rods from patients with cystic fibrosis

Journal of Clinical Microbiology

Volumn 47, Issue 10, 2009, Pages 3283-3288

  Otto Karg, Ines ^a,b   Jandl, Stefanie ^a   Müller, Tobias ^a   Stirzel, Beate ^a   Frosch, Matthias ^a   Hebestreit, Helge ^a   Abele Horn, Marianne ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; TOBRAMYCIN;

ANALYTICAL ERROR; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; COMPUTER PROGRAM; CONTROLLED STUDY; CYSTIC FIBROSIS; GRAM NEGATIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; CYSTIC FIBROSIS; DIAGNOSTIC ERRORS; FRANCE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; SOFTWARE;

NEGIBACTERIA;

EID: 70349641146     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00505-09     Document Type: Article

References (24)

1. Bosshard, P. P., R. Zbinden, S. Abels, B. Boddinghaus, M. Altwegg, and E. C. Bottger. 2006. 16S rRNA gene sequencing versus the API 20 NE system and the Vitek 2 ID-GNB card for identification of nonfermenting gramnegative bacteria in the clinical laboratory. J. Clin. Microbiol. 44:1359-1366.
2. Brisse, S., S. Stefani, J. Verhoef, A. Van Belkum, P. Vandamme, and W. Goessens. 2002. Comparative evaluation of the BD Phoenix and Vitek 2 automated instruments for identification of isolates of the Burkholderia cepacia complex. J. Clin. Microbiol. 40:1743-1748.
3. Burns, J. L., L. Saiman, S. Whittier, J. Krzewinski, Z. Liu, D. Larone, S. A. Marshall, and R. N. Jones. 2001. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 39:257-260.
4. Burns, J. L., L. Saiman, S. Whittier, D. Larone, J. Krzewinski, Z. Liu, S. A. Marshall, and R. N. Jones. 2000. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J. Clin. Microbiol. 38:1818-1822.
5. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing, vol.27; 15th informational supplement. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Food and Drug Administration. 2003. Class II special controls guidance document: antimicrobial susceptibility test systems; guidance for industry. Food and Drug Administration, Washington, DC.
7. Funke, G., and P. Funke-Kissling. 2004. Evaluation of the new VITEK 2 card for identification of clinically relevant gram-negative rods. J. Clin. Microbiol. 42:4067-4071.
8. Funke, G., D. Monnet, C. deBernardis, A. von Graevenitz, and J. Freney. 1998. Evaluation of the VITEK 2 system for rapid identification of medically relevant gram-negative rods. J. Clin. Microbiol. 36:1948-1952.
9. Goldenberger, D., A. Künzli, P. Vogt, R. Zbinden, and M. Altwegg. 1997. Molecular diagnosis of bacterial endocarditis by broad-range PCR amplification and direct sequencing. J. Clin. Microbiol. 35:2733-2739.
10. Reference deleted.
11. Jossart, M. F. G., and R. J. Courcol. 1999. Evaluation of an automated system for identification of Enterobacteriaceae and nonfermenting bacilli. Eur. J. Clin. Microbiol. Infect. Dis. 18:902-907.
12. Joyanes, P., M. del Carmen Conejo, L. Martinez-Martinez, and E. J. Perea. 2001. Evaluation of the Vitek 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples. J. Clin. Microbiol. 39:3247-3253.
13. Kiska, D. L., and P. H. Gilligan. 2004. Pseudomonas. In R. R. Murray, E. J. Baron, J. H. Jorgensen, M. H. Pfaller, and R. H. Yolken (ed.), Manuel of clinical microbiology, 8th ed. American Society for Microbiology, Washington, DC.
14. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
15. Mahenthiralingam, E., J. Bischof, S. K. Byrne, C. Radomski, J. E. Davies, Y. Av-Gay, and P. Vandamme. 2000. DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J. Clin. Microbiol. 38:3165-3173.
16. Monnet, D., D. Lafay, M. Desmonceaux, J. F. Allard, and J. Freney. 1994. Evaluation of a semi-automated 24-hour commercial system for identification of Enterobacteriaceae and other gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 13:424-430.
17. Reference deleted.
18. National Committee for Clinical and Laboratory Standards. 2001. Development of in vitro susceptibility testing criteria and quality control parameters, p. i-29, 2nd ed. Approved guideline M23-A2. National Committee for Clinical and Laboratory Standards, Wayne, PA.
19. Sader, H. S., T. R. Fritsche, and R. N. Jones. 2006. Accuracy of three automated systems (MicroScan WalkAway, Vitek, and Vitek 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum betalactam agents. J. Clin. Microbiol. 44:1101-1104.
20. Saiman, L., J. L. Burns, D. Larone, Y. Chen, E. Garber, and S. Whittier. 2003. Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J. Clin. Microbiol. 41:492-494.
21. Saiman, L., J. L. Burns, S. Whittier, J. Krzewinski, S. A. Marshall, and R. N. Jones. 1999. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J. Clin. Microbiol. 37:2987-2991.
22. Saiman, L., F. Mehar, W. W. Niu, H. C. Neu, K. J. Shaw, G. Miller, and A. Prince. 1996. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23:532-537.
23. Shelly, D. B., T. Spilker, E. J. Gracely, T. Coenye, P. Vandamme, and J. J. LiPuma. 2000. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J. Clin. Microbiol. 38:3112-3115.
24. Wellinghausen, N., J. Kothe, B. Wirths, A. Sigge, and S. Poppert. 2005. Superiority of molecular techniques for identification of gram-negative, oxidasepositive rods, including morphologically nontypical Pseudomonas aeruginosa, from patients with cystic fibrosis. J. Clin. Microbiol. 43:4070-4075.